Venous Stents Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Venous Stents Market Trends and Insights

Rising Prevalence of Chronic Symptomatic Venous Diseases

Post-thrombotic syndrome affects up to 50% of patients after deep vein thrombosis, and earlier detection is funneling more candidates toward intervention^{[1]Raghu Kolluri, “Consensus Statement on the Management of Nonthrombotic Iliac Vein Lesions,” Circulation: Cardiovascular Interventions, ahajournals.org} . The VERNACULAR study reported 84.0% primary patency at 36 months for modern stents, underscoring their value in difficult cases. Growing awareness of May-Thurner syndrome among younger adults is widening the treated population. These epidemiologic shifts are most evident in markets with robust vascular specialization and aging demographics. As a result, the venous stents market is poised to benefit from sustained procedure growth over the forecast horizon.

Ageing Population Boosting Venous Interventions

Populations aged 65+ experience higher chronic venous insufficiency, prompting guideline updates that advocate earlier stenting when conservative therapy fails.^{[2]Joakim Nordanstig, “ESVS 2024 Clinical Practice Guidelines,” esvs.org} Geriatric patients often present with multimorbidity, so devices designed for shorter procedure times and lower anticoagulation needs are gaining favor. Japan and Western Europe exemplify how super-aged societies accelerate adoption of minimally invasive venous treatments. These macro-demographics give the venous stents market a durable, long-term growth underpinning.

Dedicated Nitinol Venous Stents Gaining Regulatory Approvals

FDA clearance of purpose-built platforms such as the Abre stent, which achieved 81.6% three-year patency with no fracture events, validates superior design tailored to venous anatomy. Europe is now harmonizing approval criteria around quality-of-life endpoints, further smoothing pathways for new entrants. Clearer regulatory definitions distinguish venous from arterial devices, prompting companies to fund specialized R&D and physician training programs. These developments expand the venous stents market as a distinct therapeutic category.

Favourable Reimbursement for Outpatient Venous Procedures

Medicare and several private insurers now reimburse same-day venous stenting performed in ASCs, lowering total episode costs while preserving outcomes. Bundled payments that include imaging, stent placement and surveillance support integrated care pathways. Clinicians are incentivized to adopt standardized protocols, helping drive procedural migration from inpatient to outpatient settings. This economic tailwind is particularly strong in the United States and certain EU markets, amplifying overall market demand.

High Procedure Cost & Limited Patient Awareness

Total treatment cost can exceed USD 15,000 in systems without strong coverage, limiting access in lower-income regions. Many patients remain unaware that minimally invasive venous therapies exist, and community clinics often lack the imaging needed for diagnosis. Education campaigns aimed at primary care and the public are critical to expanding the venous stents market. Without them, underdiagnosis will continue to suppress demand despite clinical efficacy.

In-Stent Restenosis / Re-Occlusion Risk

Re-stenosis, although less frequent with modern designs, still poses a concern for clinicians managing complex anatomy. Follow-up imaging requirements add cost and can deter patients in price-sensitive markets. Development of drug-eluting and polymer-coated stents seeks to mitigate this risk, but long-term data remain a prerequisite for widespread adoption.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Application: Pelvic Interventions Drive Growth

Leg interventions generated the largest revenue in 2025, capturing 43.16% of the venous stents market size because post-thrombotic iliofemoral obstruction remains the most common indication. Pelvic procedures, fueled by heightened recognition of May-Thurner syndrome, will outpace all other segments at a 12.28% CAGR. TOPOS trial data showing 90% 12-month patency for oblique nitinol stents in common iliac compression underpin this momentum.Emergence of dedicated protocols for chronic pelvic pain is channeling younger patients toward intervention, expanding total addressable volume.

Rising use of IVUS and venography in office-based labs elevates diagnostic accuracy for pelvic lesions, improving patient selection and outcomes. ASCs leverage shorter recovery times to attract these cases, supporting outpatient expansion within the venous stents market. Meanwhile, abdominal IVC and renal vein work remains niche, and chest interventions for superior vena cava syndrome are largely confined to tertiary centers. Collectively, these trends diversify procedural mix and reinforce long-term market vitality.

By Disease: Non-Thrombotic Lesions Gain Momentum

Chronic deep vein thrombosis retained 39.20% venous stents market share in 2025, but non-thrombotic iliac vein lesions will log an 11.17% CAGR through 2031 as clinicians diagnose compression earlier. Abre stent data revealing 97.1% three-year patency in NIVL patients bolsters confidence. Post-thrombotic syndrome, with its collateral burden, still commands large volumes, yet improved algorithms segregate thrombotic from non-thrombotic cases more effectively.

Expanding indications now include venous claudication and chronic pelvic pain, broadening the candidate pool. Acute DVT cases increasingly see adjunctive stenting following thrombectomy to maintain flow. Future growth will depend on payer recognition of these new indications and continued performance of dedicated devices across lesion types.

By Stent Type: Drug-Eluting Platforms Emerge

Self-expanding nitinol devices delivered 58.95% revenue in 2025, reflecting proven reliability and ease of deployment. Drug-eluting designs, however, will post the leading 11.86% CAGR as trials confirm lower neointimal proliferation. Polymer advancements enable sustained paclitaxel delivery tailored to low-pressure venous flow, pushing adoption further. Covered stents occupy a specific niche in rupture-prone or highly calcified anatomy, while balloon-expandable products gradually decline in favor.

The venous stents market is entering a precision-therapy phase in which combination treatments pair pharmacology with mechanical scaffolds. Manufacturers capable of demonstrating long-term superiority through head-to-head studies will capture share as value-based procurement gains ground.

By Material: Polymer Innovation Accelerates

Nitinol continues to dominate with 71.80% venous stents market share given unmatched super-elasticity. Yet polymer-enhanced constructs will grow 11.62% annually, aiming to curb thrombogenicity and deliver drugs efficiently. Elgiloy and cobalt-chromium solutions serve smaller sub-segments demanding radiopacity or controlled expansion. Stainless steel’s proportion will keep shrinking as newer alloys prove safer and more adaptable.

Material science breakthroughs enable thinner struts that preserve radial strength, aiding deliverability through tortuous venous anatomy. Radiopaque markers integrated into polymer coatings improve intra-procedural visualization, reducing fluoroscopy time and contrast load. Together, these advances sustain a robust innovation pipeline and deepen competitive differentiation.

By End-User: ASC Growth Transforms Care Delivery

Hospitals managed 61.55% of global revenue in 2025, but the ASC channel is expanding at 12.41% CAGR as outpatient models gain payer endorsement. Conscious sedation protocols and smaller access profiles shorten recovery, making same-day discharge realistic for most uncomplicated cases. Specialty vein clinics, often physician-owned, bundle imaging, intervention and surveillance, offering a streamlined patient experience that appeals to cost-conscious insurers.

Regulatory frameworks in the United States provide facility fee parity that supports this shift. Other regions are watching closely, and as reimbursement aligns, the venous stents market will see a more balanced distribution between inpatient and outpatient venues. Device makers now tailor training and support specifically for ASC staff to accelerate adoption.

Geography Analysis

North America retained 38.25% of 2025 revenue thanks to mature reimbursement, extensive ASC networks and rapid uptake of newly approved stents. Dedicated registries and post-market studies reinforce safety, encouraging early use in complex disease. Multidisciplinary vascular teams integrate stenting into comprehensive care pathways, supporting procedure volumes across both hospital and outpatient settings.

Europe contributes substantial scientific output and follows standardized treatment algorithms laid out by the 2024 ESVS guidelines. Country-level reimbursement disparities, however, create uneven adoption. Germany and the United Kingdom spearhead clinical research, influencing neighboring markets. Brexit-related regulatory divergence introduces some approval uncertainty, yet demographic drivers and robust evidence maintain steady growth.

Asia-Pacific will post the fastest 11.24% CAGR as infrastructure improves and awareness rises. China’s insurance reforms and Japan’s aging demographic are key catalysts, though limited specialist density restrains some local uptake. International manufacturers are investing in physician education and localized production to navigate complex regulatory pathways. India and Southeast Asia represent longer-term opportunities once procedural capacity broadens.

Regulatory Landscape

US regulatory pathways for dedicated venous stents remain high-scrutiny for implantable vascular devices, with FDA oversight of labeling and lifecycle changes via supplements when evidence changes. In February 2026, Philips Image Guided Therapy Corporation received FDA approval for a PMA supplement (P230021/S003) for the Duo Venous Stent System to update the instructions for use incorporating final results from the VIVID clinical study, underscoring the importance of post-approval evidence and labeling control for venous indications.

Value Chain Analysis

The venous stent value chain begins with specialty inputs such as medical-grade nitinol, engineered polymers, coating chemistries for surface modification, radiopaque markers, and catheter delivery components. Component manufacturing relies on laser cutting, electropolishing, heat setting, and cleanroom assembly, with validation-heavy testing and change-control documentation shaping regulatory submissions and lifecycle management.

Market Opportunities and Future Outlook

Opportunity is expanding around purpose-built deep venous indications and broader geographic availability of dedicated platforms, reducing reliance on off-label arterial devices for complex venous anatomy. In January 2026, Gore and Associates announced US FDA approval for the GORE VIABAHN FORTEGRA Venous Stent for deep venous disease in the IVC, iliac, and iliofemoral veins, and in June 2026 announced CE Mark (MDR) approval for the same system in Europe for symptomatic IVC and iliofemoral venous outflow obstruction. These approvals widen the labeled addressable pool in high-volume regions and sharpen competitive differentiation around deep venous and iliocaval disease pathways.